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The varicella zoster virus (VZV) IE63 protein is required for growth of the virus in cell culture and is expressed during both
lytic and latent phases of VZV infection. We have investigated the physical and functional interaction of this protein with the
major VZV transactivating protein IE62. The region of the IE63 protein required for interaction with the IE62 protein has been
identified and encompasses the N-terminal 142 amino acids. We have found that the interaction is stable at physiological
ionic strength. We have also shown that a portion of the IE63 and IE62 proteins colocalize in VZV-infected cells at both 15
and 48 h postinfection. IE63 was found to have no transcriptional activating or repressing activity within the context of a
minimal VZV glycoprotein promoter. The presence of the IE63, however, upmodulated the IE62 transactivation of thisinfected cell extracts, indicating that it is present in a com
INTRODUCTION
Varicella zoster virus (VZV) is a member of the Alpha-
herpesvirus subfamily of the family Herpesviridae and is
the causative agent of chickenpox (varicella) during pri-
mary infection and shingles (herpes zoster) after reacti-
vation from latency (Arvin, 1996). The viral genome en-
codes some 71 open reading frames (ORFs; Davison and
Scott, 1986). During lytic infection all of the VZV ORFs are
believed to be expressed in a sequential cascade com-
posed of three broad kinetic classes, immediate-early
(IE), early (E), and late (L), characteristic of all herpesvi-
ruses (Cohen and Straus, 1996; Ruyechan and Hay,
1999).
During latent infection, only a small subset of VZV
ORFs is expressed. These include ORFs 4, 21, 29, 62, and
63 (Cohrs et al., 1996; Croen et al., 1988; Hay and
Ruyechan, 1994; Kennedy et al., 2000; Lungu et al., 1998).
This situation is in direct contrast to that observed with
other alphaherpesviruses where only the latency asso-
ciated transcript and ORFs derived from that transcript
are expressed. Thus, the mechanism(s) of latent VZV
infection appears to be unique and an understanding of
the functions of the various proteins encoded by the
ORFs expressed during both lytic and latent infection is
a fundamental requirement for our understanding of the
biology of VZV infection. The work reported here concen-
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trates on the nature and function of the interaction be-
tween two of these proteins, IE62 and IE63.
The VZV IE62 is encoded by ORFs 62 and 71 within the
inverted repeat sequences bounding the US region of the
VZV genome. IE62 is the major VZV transcriptional reg-
ulatory protein and activates expression of all three ki-
netic classes of viral genes. It is homologous in large
part to HSV ICP4, but unlike that protein IE62 possesses
a potent N-terminal acidic activation domain (Perera et
al., 1992a, 1992b, 1993). IE62 is expressed as an IE
protein during the replication cycle and is localized to the
nucleus during early times of infection (Shiraki and Hy-
man, 1987). IE62 is phosphorylated by the viral ORF47
and ORF66 kinases and cellular casein kinase II (CKII)
(Kenyon et al., 2001; Kinchington et al., 2001; Ng et al.,
1994). At late times in infection, the IE62 protein is incor-
porated into the viral tegument in a process mediated by
the VZV ORF66 kinase (Kinchington et al., 2001). Thus
IE62 is present immediately upon infection and is be-
lieved to enter the nucleus along with the viral DNA
where it can play a critical role in triggering and regu-
lating the replicative cycle of VZV. IE62 has recently been
shown to directly interact with the VZV IE4 and IE63
proteins (Spengler et al., 2000; Sommer et al., 2001).
The IE63 protein is encoded by VZV ORFs 63 and 70
and is the putative homologue of HSV ICP22. Unlike that
protein, however, IE63 has recently been shown to be
required for growth in cell culture (Sommer et al., 2001)
and is incorporated into the virion tegument (Kinchington
et al., 1995). The predicted molecular weight of IE63 is
30.5 kDa (Davison and Scott, 1986) as compared to apromoter. Finally, we show that the IE63 protein can be c
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region of similarity between IE63 and ICP22 lies within
the carboxy-terminal portions of the two proteins and is
quite limited (25–49%). Thus the VZV IE63 protein ap-
pears to be both functionally and structurally distinct
from ICP22.
Currently, a limited amount of information is known
concerning the properties and functions of IE63. It is
synthesized as an IE protein in lytic infection and local-
izes to the nucleus (Debrus et al., 1995). Sequences
close to the carboxy terminus of IE63 are required for its
efficient nuclear localization (Stevenson et al., 1996). IE63
from infected MeWo cells is approximately 44 kDa. IE63
is phosphorylated in infected cells and can be phosphor-
ylated in vitro by casein kinase II (Stevenson et al., 1996).
More recently IE63 has been found to be heavily phos-
phorylated by, and tightly bound to, the VZV ORF47 ki-
nase in in vitro assays using recombinant proteins
(Kenyon et al., 2001). During latency (as judged by in situ
hybridization and immunohistochemistry of human neu-
ronal tissue and from neuronal tissue derived from ani-
mal models), ORF63 is the gene which is most abun-
dantly expressed at the levels of both mRNA and protein.
ORF63 is also believed to be expressed early in human
tissue during reactivation (Debrus et al., 1995; Ma-
halingam et al., 1996; Sadzot-Delvaux et al., 1995).
Thus far, only a few studies have been done regarding
the function of IE63. These have been directed toward a
possible role in VZV gene expression analogous to that
observed with ICP22 in HSV infection. IE63 has been
reported to repress the activity of the VZV IE62 promoter
and activate the thymidine kinase promoter in the ab-
sence of other VZV proteins (Jackers et al., 1992). In
contrast a more recent publication showed that IE63 had
essentially no transactivating or transrepressing activity
on VZV promoters (Kost et al., 1995). The possible roles
and functions of IE63 during latency have not, as yet,
been investigated due, in part, to the lack of an experi-
mental model system.
In the work presented here we have further investi-
gated the nature of the interaction between IE63 and
IE62, including mapping of the region of IE63 required for
binding of IE62. We also show that IE63 modulates the
IE62-mediated activation of the VZV gI promoter and that
IE63 can be coimmunoprecipitated from infected cell
protein extracts with antibodies directed against the host
cell RNAP II.
RESULTS
The IE63/IE62 interaction occurs at physiological salt
concentrations
We have recently shown that a direct physical interac-
tion occurs between IE63 and IE62 using coimmunopre-
cipitation from infected cell extracts and an ELISA-bind-
ing assay using recombinant proteins (Sommer et al.,
2001). In order to further characterize this interaction,
IE63 was coprecipitated with IE62 from infected MeWo
cell nuclear extracts using the monoclonal H6 IE62
antibody. The coimmunoprecipitations were performed
at increasing NaCl concentrations in order to assess the
ionic strength dependence of the binding. The percent-
age of input IE62 and IE63 precipitated was quantified by
densitometry comparing the signal obtained in the assay
with the signal of a known aliquot of the nuclear extract.
In the results shown in Fig. 1, 26, 30, and 28% of the input
IE62 was precipitated at 100, 150, and 200 mM NaCl,
respectively, indicating that the IE62/antibody interaction
was stable under these conditions. In contrast, 1.5% of
the input IE63 was coprecipitated at 100 mM NaCl and
0.5% at 150 mM. No coimmunoprecipitation of IE63 was
detected at NaCl concentrations of 200 mM (Fig. 1) or
above (data not shown). Thus the IE62/IE63 interaction is
detectable at or near physiological salt concentrations
but is more sensitive to ionic strength than the interac-
tion recently demonstrated between IE62 and the VZV
IE4 protein, which was stable at NaCl concentrations up
to 350 mM (Spengler et al., 2000). These results also
indicate that only a fraction of the IE62 and IE63 present
in the nuclear extracts are present in a complex.
Identification of the region of IE63 required for
interaction with IE62
The region of IE63 required for interaction with IE62
was identified using protein affinity pulldown assays.
These experiments made use of three maltose-binding
protein (MBP)-IE63 fusions previously generated in our
laboratory (Stevenson et al., 1996). These include a full-
length IE63-MBP fusion and two IE63 carboxy-terminal-
truncations, 63K and 63N, which contain amino acids
1–210 and amino acids 1–142 of IE63, respectively. The
three fusion proteins were expressed in Escherichia coli
and captured on amylose beads as described under
FIG. 1. Ionic strength dependence of the IE63/IE62 interaction. Co-
immunoprecipitations were performed at NaCl concentrations ranging
from 100 mM to 1 M using the monoclonal H6 antibody against IE62.
The data presented here are for 100, 150, and 200 mM and show that
200 mM salt abolished the ability of the antibody to coprecipitate IE63.
The percentages of IE62 and IE63 present in the immunoprecipitates
were determined by densitometry relative to the signal from loading
controls consisting of serial dilutions of the infected cell nuclear ex-
tract.
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Materials and Methods. Purified recombinant IE62 ex-
pressed in baculovirus was then adsorbed to the beads,
which were washed extensively. Proteins bound to the
beads were eluted by boiling in SDS–PAGE buffer and
separated on 10% SDS–acrylamide gels and the pres-
ence of IE62 was detected by immunoblotting. The re-
sults are presented in Fig. 2 and show that all three MBP
fusion proteins bound IE62 to similar extents whereas
little or no binding was observed to MBP. These results
indicate that IE62 binds to the N-terminal half of IE63
(Fig. 2C). This region contains two predicted protein
kinase C sites and one predicted CKII site, but not the
nuclear localization signal nor a cluster of predicted CKII
sites known to be capable of being phosphorylated in
vitro.
Colocalization of IE62 and IE63 during infection
Based on the evidence for a direct protein–protein
interaction between IE63 and IE62, confocal microscopy
was performed on VZV-infected MeWo cells at two dif-
ferent times during infection to examine the occurrence,
extent, and timing of colocalization of the two proteins.
Previous studies have shown that this technique is
uniquely suited for examining the temporal regulation of
VZV gene expression and the progression of cell-to-cell
spread of the virus in tissue culture (Santos et al., 1998,
2000).
Due to the highly cell-associated nature of VZV and the
fact that purified virions show very low infectivity and
often appear damaged, MeWo cell monolayers were
infected with suspensions of MeWo cells harvested at
late stages of VZV infection at a ratio of one infected cell
to eight uninfected cells. The intracellular localizations of
IE63 and IE62 were then determined by confocal micros-
copy using antisera specific for each of the proteins.
Inoculum cells are visible as positive for IE62 shortly
after the infection is passed (4 h p.i.). Obviously positive
cells are relatively few in number and IE62 is present in
both the cytoplasm and the nucleus. At early timepoints
(12–15 h p.i.), IE62 is produced in newly infected cells
FIG. 2. Mapping of the region of IE63 required for IE62 binding. (A) Protein affinity pulldown assay results. Recombinant IE62 bound to MBP-fusion
constructs of IE63 was visualized by immunoblotting with rabbit polyclonal IE62 antibody. Lane 1, full length IE63; lane 2, 63K; lane 3, 63N; lane
4, MBP. (B) Schematic of the positions of the C-terminal IE63 truncations. (C) Map of IE63 showing the position of the IE62 binding region relative
to predicted CKII and PKC sites (Blom et al., 1999) and the putative nuclear localization signal (Stevenson et al., 1996).
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surrounding inoculum cells and accumulates only in the
nuclei of these cells. At late timepoints (24–48 h p.i.), IE62
is no longer shuttled to the nucleus and accumulates in
the cytoplasm (Kinchington et al., 2000), and infected
cells fuse into large, multinucleate syncytia. Cell–cell
spread continues beyond the syncytia and areas of the
monolayer in early stages of infection are often observed
beyond a syncytium boundary (Santos et al., 1998). Thus,
all stages of VZV infection may be observed within one
field. For the purposes of this analysis, large syncytia and
both cytoplasmic and nuclear staining for IE62 are indic-
ative of late infection, cells exhibiting only nuclear stain-
ing of IE62 are indicative of early infection, and unin-
fected cells did not immunostain for either IE62 or IE63.
At early stages (15 h postinfection), IE62 and IE63
colocalized in the infected cell nuclei (Fig. 3A). IE63
(green, panel 2) was localized to the nuclei (blue, panel
1) in early stage infected cells surrounding one infected
cell from the VZV-infected MeWo inoculum (which shows
substantial cytoplasmic staining for IE62). IE62 (red,
panel 3) was also localized to the nuclei of these cells,
albeit in a more restricted pattern, and IE62 and IE63
colocalized perfectly in several nuclei (panel 4). In late
stage infection (Fig. 3B), IE62 (panel 7) had largely relo-
FIG. 3. Colocalization of IE63 and IE62 in infected cells. (A) Cells 15 h postinfection showing an inoculum cell surrounded by early phase infected
cells (40). Panel 1, nuclei stained with TOTO-3 (blue); panel 2, staining with IE63 antibody (green); panel 3, staining with IE62 antibody (red); panel
4, merged images from panels 1–3. For the merged images colocalization of red and green  yellow; colocalization of red, green, and blue  white.
(B) Cells 48 h postinfection. Panel 5, TOTO-3 staining; panel 6, staining with IE63 antibody; panel 7, staining with IE62 antibody; panel 8, merged
images. (C) Cells 48 h postinfection (100). Panel 9, TOTO-3 nuclear staining; panel 10, staining with IE63 antibody; panel 11, staining with IE62
antibody; panel 12, merged images. (D) Mock infected cells at 48 h (40). Panel 13, TOTO-3 nuclear staining; panel 14, staining with IE63 antibody;
panel 15, staining with IE62 antibody; panel 16, merged images.
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calized from the nuclei of the syncytia into the cytoplasm,
and some IE63 (panel 6) had also relocalized to the
cytoplasm. A small amount of IE62 remained in the nu-
cleus in discrete foci and IE63 colocalized with the IE62
in these foci but also was present in other areas of the
nuclei. In cells outlying the large, central syncytium, IE62
was present in the cytoplasm and the nuclei, whereas
IE63 remained nuclear. Mock-infected MeWo cells used
as controls showed only nuclear staining with TOTO-3.
No IE62 or IE63 staining was observed confirming the
specificity of the antibodies (Fig. 3D).
In order to confirm the observations in late-infected
cells, images were obtained at a magnification of 100.
Figure 3C shows that at this magnification subdomains
within the nuclei of a small syncytium were clearly visi-
ble. IE63 staining was observed over large areas of most
of the nuclei and at relatively low levels in the cytoplasm,
whereas IE62 staining was present in restricted foci of
the syncytial nuclei and substantial amounts of IE62
were localized to the cytoplasm. IE63 and IE62 were
colocalized within the nuclear foci staining for IE62
(panel 12). In the single cell present in the upper right
quadrant of the panels in Fig. 3C and peripheral to the
syncytium, IE63 staining is observed only in the nucleus,
whereas IE62 staining is present both in nuclear foci and
in the cytoplasm. Thus the results from the confocal
microscopy analysis indicate that a fraction of the IE63
and IE62 proteins colocalize within nuclei at both early
and late stages of infection and suggest that cytoplasmic
accumulation of IE62 at late stages of infection occurs
earlier and to a greater extent than cytoplasmic accumu-
lation of IE63. Comparison of Figs. 3A and 3B indicates
the specificity of the assay in that the intracellular local-
ization of IE62 and IE63 could be clearly distinguished at
early versus late stages of infection.
IE63 upmodulates IE62 transactivation of the VZV gI
promoter
Transient transfection assays were performed using a
reporter plasmid containing elements of the VZV glyco-
protein I (gI) promoter driving expression of chloram-
phenicol acetyltransferase (CAT) to determine if IE63
plays a functional role with regard to IE62 transactivation
of this promoter. The promoter element used (designated
gI3.4) contained only the gI TATA box and a 20-bp se-
quence upstream of the TATA box which contains over-
lapping USF and Sp1 binding sites, both of which are
important for IE62 activation. This 20-bp element has
been designated the activating upstream sequence or
AUS (Kantakamalakul et al., 1995; He et al., 2001). The
TATA box and AUS represent, to the best of our knowl-
edge, the minimal sequences required for IE62 activation
of the gI promoter. The results of triplicate assays are
shown in Fig. 4 and indicate that IE63 has no significant
FIG. 4. IE63 modulation of IE62 transactivation. A reporter plasmid
containing a CAT reporter gene under the control of the VZV gI3.4
minimal promoter element was transfected into T cells in the presence
or absence of plasmids expressing IE63 and IE62. All assays were
performed in triplicate. IE63 alone did not affect expression of CAT but
did upmodulate the observed IE62 transactivation.
FIG. 5. Magnetic bead recruitment assays. Magnetic bead recruit-
ment assays were performed in order to assess the ability of IE63 and
IE62 to interact directly with the gI3.4 promoter. (A) Assays using
infected cell extracts. Lane 1, positive control, 1.7 g of nuclear protein
extract; lanes 2–4, eluants from the immobilized template using 0.5, 1.0,
and 2.0 mg of total protein from the extract, respectively. The top and
bottom panels were probed with rabbit polyclonal IE62 and IE63
antibodies, respectively. The results show that in infected cell nuclear
extracts, both proteins are recruited to the promoter. (B) Recruitment of
recombinant IE62 and IE63. Twenty micrograms of recombinant IE62
and 20 g of recombinant IE63 were added either individually or
together to 0.25 mg of nuclear protein extract from uninfected MeWo
cells. The eluants from the immobilized template were then analyzed by
immunoblot using IE62 (top) and IE63 (bottom) antibodies. The third
lane in each panel contains a positive control representing 0.1 input
of the reaction mix containing both recombinant IE62 and IE63-MBP.
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intrinsic transactivating or transrepressing activity under
these experimental conditions. In contrast, the presence
of IE63 resulted in a significant increase (approximately
4-fold) over the activation observed with IE62 alone un-
der these conditions. Two additional experiments in
which the total amount of DNA in the transfection mix-
tures was adjusted to 20 g by addition of carrier DNA
yielded increases of 4-fold and 3.9-fold. Similar results
were obtained using a CAT reporter plasmid (pgICAT)
containing the entire intergenic sequence which lies
downstream of VZV ORF66 (encoding a viral kinase) and
upstream of ORF67 (encoding gI) based on the orienta-
tion of these ORFs in the VZV genome (Davison and
Scott, 1986; Ling et al., 1992) (data not shown). Thus no
additional cis-acting sequences beyond those contained
in the gI3.4 minimal promoter are required for or involved
in the IE63 enhancement of IE62 transactivation.
IE62 facilitates recruitment of IE63 to the gI3.4
promoter
Magnetic bead recruitment assays were performed to
determine if the upmodulation of IE62 transactivation of
the gI3.4 promoter by IE63 (as shown by the CAT assay
results) correlates with IE63 binding to the promoter
DNA. An oligonucleotide containing the gI3.4 promoter
element was biotinylated and coupled to streptavidin-
coated magnetic beads. Infected MeWo nuclear extract
(500 g, 1 mg, or 2 mg) was then added and the reaction
mixture was incubated at 4°C for 1 h. The beads were
washed and bound proteins were eluted and analyzed
by SDS–PAGE and Western blot analysis. The results
presented in Fig. 5A show that both IE63 and IE62 were
present on beads containing the promoter DNA and that
there was a striking enrichment of the ratio of IE63 to
IE62 bound as compared to the results obtained in the
coimmunoprecipitation experiments. Quantification of
the amounts of each protein bound relative to loading
controls showed that 3.3% of input IE62 and 2.6% of input
IE63 were eluted when 500 g of infected nuclear extract
was used, 7.4% of the IE62 and 5.5% of the IE63 were
eluted when 1 mg of extract was used, and 16.7% of IE62
and 6.3% of IE63 were eluted in the reactions containing
2 mg of nuclear extract. It is not clear why proportionately
less IE63 was bound at the highest concentration of
protein extract used, whereas the fraction of IE62 bound
increased. Since not all of the IE62 is complexed with
IE63 in the extracts, as demonstrated by the coimmuno-
precipitation experiments, it is possible that as increas-
ing amounts of the nuclear extract was added to the
beads free IE62 could out compete an IE62/IE63 com-
plex in this in vitro situation.
IE62 either binds the DNA directly or is possibly re-
cruited to the DNA by USF and/or Sp1 (H. He, H. Peng
and W. Ruyechan, unpublished data). These two tran-
scription factors specifically bind the AUS of gI3.4 (He et
al., 2001). In order to determine if IE63 also binds to the
gI3.4 promoter DNA or was present in the magnetic bead
eluants due to its interaction with IE62, additional recruit-
ment assays using recombinant IE62 and IE63 were
performed. In these assays recombinant IE62 and IE63-
MBP were added either individually or together to nu-
clear extracts derived from uninfected cells. The results
of these experiments are presented in Fig. 5B and show
that the recombinant baculovirus-derived IE62 bound to
the gI3.4 promoter in both the presence and the absence
of the IE63-MBP. In contrast, recombinant IE63/MBP was
associated with the promoter in the presence but not in
the absence of the recombinant IE62. Moreover, the
relative levels of the recombinant proteins bound were
similar to those seen with the native proteins in infected
cell protein extracts.
IE63 associates with the cellular RNA polymerase II
In order to gain further insight into the possible mech-
anism of the transcriptional modulatory function of IE63,
immunoprecipitation experiments were performed to de-
termine if IE63 associated with the cellular RNA polymer-
ase II (RNAP II). ICP22, the HSV homologue of IE63, has
been implicated in alteration of the phosphorylation state
of the host cell RNAP II large subunit during infection and
in loss of the general transcription factor TFIIE from the
RNAP II holoenzyme (Rice et al., 1994, 1995; Jenkins and
Spencer, 2001). Protein G–Sepharose-enhanced coim-
munoprecipitation experiments from infected cell nu-
clear extracts were performed using a monoclonal anti-
body against the RBP8 subunit of RNAP II and a rabbit
polyclonal antibody against IE63. The results presented
in Fig. 6A show that the RNAP II antibody coprecipi-
tated IE63. Conversely, the IE63 antibody coprecipi-
tated the large subunit of RNAP II. As controls for the
specificity of the IE63/RNAP II interaction we used anti-
bodies directed against two subunits (RPA70 and RPA32)
of the abundant nuclear host cell DNA-binding protein,
replication protein A (RPA). RPA70, RPA32, and an addi-
tional subunit, RPA14, form a heterotrimeic complex
which functions in DNA replication, recombination, and
repair and which has also been shown to bind to specific
sites within upstream transcriptional regulatory se-
quences of cellular genes (reviewed in Wold, 1997).
Results from these experiments are presented in Figs.
6B and 6C. The top panel in Fig. 6B shows that mono-
clonal antibodies against the RPA32 and RPA70 subunits
did not coprecipitate IE63, whereas the RNAP II mono-
clonal antibody did. The bottom panel shows that a rabbit
polyclonal antibody against the RPA32 subunit did not
coprecipitate RNAP II, whereas the IE63 rabbit poly-
clonal did. Thus these experiments have also controlled
for possible artifacts with rabbit versus mouse derived
antibodies. The top panel in Fig. 6C shows that the
RPA32 polyclonal precipitated RPA32, whereas the
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polyclonal IE63 antibody did not. The middle panel of
Fig. 6C shows that the RPA32 monoclonal was able to
precipitate RPA32, whereas the monoclonal RNAP II did
not. Finally, the bottom panel shows that the 63 poly-
clonal antibody was not capable of precipitating the p70
subunit of RPA within detectable levels. In other control
experiments antibodies against IE63 did not coprecipi-
tate another abundant nuclear protein, DNA polymerase
 (data not shown). These results indicate that IE63 is
specifically associated with either RNAP II or a complex
containing RNAP II in VZV-infected cells.
Coimmunoprecipitations were performed at various
NaCl concentrations in order to examine the stability of
the complex containing IE63 and RNAP II. The results are
FIG. 6. Coimmunoprecipitation of IE63 and cellular RNAP II. (A) Eluants from anti-RNAP II monoclonal RPB8 antibody-coupled protein G–Sepharose
beads and protein G–Sepharose beads alone probed with IE63 antibody (top) and eluants from IE63 antibody-coupled protein G–Sepharose beads
and protein G–Sepharose beads alone probed with RNAP II monoclonal antibody B1 (bottom). The first lane in both panels contains the indicated
fraction of the nuclear extract used in the reactions. (B) Control experiments. Top, eluants from protein G–Sepharose coupled with the indicated
monoclonal antibodies and probed with polyclonal IE63 antibody. Bottom, eluants from protein G–Sepharose coupled with the indicated polyclonal
antibodies and probed with monoclonal RNAP II B1 antibody. (C) Control experiments. Top, eluants from protein G–Sepharose coupled with RPA32
or IE63 polyclonal antibodies and probed with RPA32 monoclonal antibody. Middle, eluants from protein G–Sepharose coupled with RPA32 or
RNAP II B8 monoclonal antibodies probed with RPA32 rabbit polyclonal antibody. Bottom, eluant from protein G–Sepharose coupled with IE63
polyclonal antibody and probed with RPA70 monoclonal antibody. The first lane is a loading control containing the indicated fraction of the nuclear
infected cell extract used in the precipitation reaction. The column to the left of the panels indicates the SDS–PAGE estimated molecular weights of
IE63 (44 kDa), the major subunit of RNAP II (210 kDa), and the RPA32 (32 kDa) and RPA70 (70 kDa) subunits of RPA. The column to the right indicates
the antibodies used to probe the respective blots. The designations m and p differentiate monoclonal versus polyclonal antibodies directed against
the RPA subunits.
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presented in Fig. 7 and show that the presence of RNAP
II in immunoprecipitates of IE63 was highly salt sensitive,
decreasing by a factor of fivefold at 150 mM NaCl as
compared to 100 mM NaCl and undetectable at salt
concentrations of 200 mM and above.
DISCUSSION
In the work presented here we have continued our
investigation of the function of the VZV IE63 protein
during lytic viral infection, further characterized its inter-
action with the viral IE62 transcriptional activator, and
shown that IE63 is associated with the cellular RNAP II in
infected cells. These results represent important new
information regarding the properties and functions of
IE63, which is expressed during both lytic and latent VZV
infection. We have previously shown that there is a direct
physical interaction between IE63 and IE62 based on an
ELISA assay using purified recombinant proteins (Som-
mer et al., 2001). The results presented here have ex-
tended our understanding of this interaction. We have
shown that the interaction can occur at NaCl concentra-
tions of 100–150 mM but not at 200 mM or above and that
the extent of the interaction is highly sensitive to ionic
strength within the detectable range, suggesting that
charge/charge interactions are involved. The experi-
ments also show that only a fraction of the total IE63 in
nuclear extracts derived from late stage infected cells is
present in complexes with IE62.
The protein affinity pulldown experiments have shown
that the N-terminal half of IE63 is involved in the inter-
action with IE62. These results as well as those previ-
ously published (Sommer et al., 2001) indicate that phos-
phorylation of IE63 by either viral or cellular kinases is
not required for its interaction with IE62 since the recom-
binant IE63 proteins used in these experiments were
expressed as MBP fusion proteins in bacteria. Moreover,
when 63N was transiently expressed in MeWo cells
metabolically labeled with 32Pi, no phosphorylation was
observed (Stevenson et al., 1996), suggesting that the
three predicted protein kinase C and one CKII phosphor-
ylation sites (Blom et al., 1999) present in that portion of
IE63 may not be utilized. In contrast, 63K, which con-
tains four additional predicted CKII sites (Fig. 2), was
phosphorylated both in situ via general metabolic label-
ing and in vitro by CKII. Thus there is a distinct possibility
that CKII-mediated phosphorylation of IE63 could modu-
late its interaction with IE62. The situation regarding the
role of phosphorylation by the ORF47 kinase is more
complex, since the ORF47 kinase is not required for
growth of the virus in MeWo cells but is required for
growth in human T cells and skin cells in SCIDhu mouse
implants (Moffat et al., 1998) and in human T cells in vitro
(Soong et al., 2000). Thus either CKII can substitute for
the ORF47 kinase in tissue culture or the ORF47 sites are
distinct and required for productive infection in specific
tissues.
The coimmunoprecipitation experiments using in-
fected MeWo cell nuclear extracts suggest that some
fraction of IE63 and IE62 colocalize in nuclei during lytic
infection. This has been confirmed by confocal micros-
copy analysis where the two proteins exhibited signifi-
cant, but not complete, colocalization during early stages
of VZV infection and a much lesser extent of colocaliza-
tion at late stages of infection. Since the nuclear extracts
used in the coimmunoprecipitations were derived from
48 h infected cells, the immunoprecipitation results ap-
pear to correlate with the fact that in late-infected cells,
IE63 is present in substantial amounts throughout the
nucleus whereas IE62 is present in small, discrete foci.
Thus, while the transient transfection assays reported
here clearly point to a role for IE63 in modulation of IE62
FIG. 8. Model for IE63 function at the gI promoter. IE62 is recruited
to the promoter by Sp1 and/or USF. IE63 is recruited via its physical
interaction with IE62 and then enters into an interaction with the
cellular transcription machinery, possibly remaining bound to IE62.
Conversely, IE63 could interact preferentially with the cellular transcrip-
tion machinery, possibly altering its structure or state of modification
(phosphorylation) while the interaction with the IE62 protein serves to
help stabilize the viral and cellular factors at the promoter. In both
cases, the presence of IE63 would serve to enhance the activity of the
IE62 protein.
FIG. 7. Salt dependence of IE63-RNAP II coimmunoprecipitation.
Coimmunoprecipitations were performed at NaCl concentrations rang-
ing from 100 mM to 1 M using the polyclonal IE63 antibody. The
presence of RNAP II was detected using the monoclonal RNAP II B1
antibody. The data presented here are for 100, 150, and 200 mM and
show that 200 mM salt abolished the ability of the IE63 antibody to
coprecipitate RNAP II. The relative amounts of RNAP II precipitated at
100 and 150 mM NaCl were determined by densitometry.
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transactivation, IE63 which is not associated with IE62 is
likely to be performing other significant functions during
viral infection.
The finding that during late infection there are sub-
stantial amounts of IE62 present in the cytoplasm along
with some IE63 is in keeping with the results of Kinch-
ington et al. (2000, 2001) regarding IE62 localization in
the cytoplasm during late stages of infection and reports
that IE62 and IE63 are components of the virion tegu-
ment, a portion of which is likely assembled in the cyto-
plasm (Kinchington et al., 1992, 1995). The data also
suggest that relocalization of IE62 from the nucleus to
the cytoplasm occurs more completely and somewhat
prior to the appearance of IE63 in the cytoplasm.
The transient transfection assays examining the effect
of IE63 on the activation of the minimal gI promoter are
in agreement with the previous findings of Kost et al.
(1995), who showed that IE63 has essentially no trans-
activating or transrepressing activity in the context of VZV
promoter expression in the absence of other viral gene
products. The data presented in this study, however,
show that IE63 is capable of enhancing the transactiva-
tion of this minimal promoter by the IE62 protein. Similar
IE63 boosts of IE62 transactivation have been observed
in preliminary experiments with promoter elements con-
trolling expression of VZV ORFs 28 and 61 (data not
shown), suggesting that the IE63 effect may be generally
upmodulatory at IE62 responsive promoters.
The two most obvious possibilities regarding the
mechanism by which IE63 modulates IE62 activity in-
volve either an interaction of IE63 with the promoter or
alteration of IE62 activity due to a protein/protein inter-
action. The results from the magnetic bead recruitment
assays indicate that recombinant IE63-MBP alone did
not interact with the promoter, whereas recombinant
IE62 protein did. In contrast, when the two recombinant
proteins were mixed, both the IE62 and the IE63-MBP
were eluted from the promoter and at relative levels
similar to those observed with the native proteins. There-
fore, despite possible caveats concerning lack of proper
modification (e.g., phosphorylation) of the bacterially de-
rived IE63-MBP, these results strongly suggest that (1)
IE63 may not directly bind to the gI3.4 promoter but
rather is recruited to it by IE62 and (2) the increase in
IE62 transactivation engendered by the presence of IE63
may be due, at least in part, to the direct protein/protein
interaction between IE63 and IE62 demonstrated by the
protein affinity pulldown results.
We have already shown that IE63 interacts with a
region of IE62 which has also been shown to interact
with the cellular transcription factors TBP and TFIIB
(Sommer et al., 2001; Perera, 2000). The region of IE63/
IE62 interaction also overlaps with the region of IE62
responsible for that protein’s DNA-binding activity (Wu
and Wilcox, 1991; Tyler and Everett, 1993). This interac-
tion with IE63 could alter the affinity and/or specificity of
IE62 binding, or it could alter the association of IE62 with
elements of the general transcription machinery (Fig. 8).
Either of these alterations could result in changes in the
ability of IE62 to activate a given promoter. In the latter
context, we have data (H. Peng, J. Lynch, and W.
Ruyechan, unpublished) which demonstrate that the
monoclonal RNAP II antibody used in this work also
coprecipitates the IE62 protein.
An alternative, although not mutually exclusive, mech-
anism by which the presence of IE63 could alter the level
of IE62 activity observed in the absence of other viral
proteins would involve interaction with or modification of
the basal transcription machinery. The IE63 HSV homo-
logue, ICP22, has been implicated in the modification of
the host RNAP II. Specifically, ICP22 is required for HSV-
induced modification of the large subunit of RNAP II in
conjunction with the HSV UL13 kinase, the homologue of
the VZV ORF47 kinase (Rice et al., 1994, 1995; Jenkins
and Spencer, 2001). Our coimmunoprecipitation data
show that in infected cells IE63 is present in a complex
which also contains the RNAP II. Thus IE63 could be
involved in altering the cellular RNAP II enzyme for more
efficient use in viral transcription as has been proposed
for HSV ICP22. Since the ORF47 kinase was not present
in the CAT assay experiments described here, our data
indicate that the IE63 modulation of IE62 transactivation
can occur independent of the VZV ORF47 kinase. This
suggests that the mode of action of IE63 could involve
several mechanisms. These possibilities are currently
under investigation.
MATERIALS AND METHODS
Cell lines and viruses
A3.01 cells, a CD4 continuous human T-cell line, and
MeWo cells, a continuous melanoma cell line, were
propagated and maintained as described by Boucaud et
al. (1998). Virus strain VZV-MSP was propagated, main-
tained as frozen stocks, and used to infect MeWo cells
monolayers as described by Sommer et al. (2001) and
Santos et al. (1998).
Plasmids
The reporter plasmids used in transfection assays
included pgICAT (Perera et al., 1992a) and pgI3.4CAT (He
et al., 2001). The reporter plasmids contained either the
full-length putative glycoprotein I promoter (pgICAT) or a
smaller region of the gI promoter up to and including the
AUS and TATA element (pgI3.4CAT) (He et al., 2001). The
effector expressing plasmids included pCMV62, a plas-
mid expressing IE62 from the cytomegalovirus IE pro-
moter (Perera et al., 1992a), and pCMV63, a plasmid
expressing IE63 from the cytomegalovirus IE promoter
(Stevenson et al., 1996).
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Antibodies
The monoclonal (H6) and rabbit polyclonal antibodies
used in these studies have been previously described by
Spengler et al. (2000). Polyclonal antibodies against IE63
were generated by the CAMBI Monoclonal Facility at the
University at Buffalo in rabbits using an IE63-GST fusion
protein (Stevenson et al., 1996; Spengler et al., 2001).
Rabbit serum containing antibodies directed against
IE63-GST was passed through a column containing GST
bound to glutathione Sepharose 4B (Amersham, Upp-
sala, Sweden) and the eluant was collected. The eluant
was then passed through a HiTrap Protein G HP column
(Amersham) in order to purify the IE63 IgG. Monoclonal
antibodies RBP1 and RBP8 directed against mammalian
RNAP II were purchased from NeoClone (Madison, WI).
Monoclonal antibodies directed against the p70 and p32
subunits of human RPA were purchased from Oncogene
Research Products (San Diego, CA). Rabbit polyclonal
antibodies directed against the p32 subunit of RPA and
monoclonal antibodies directed against mammalian
DNA polymerase  were obtained from Dr. Thomas Me-
lendy (University at Buffalo).
Quantification of immunoblots
The relative amounts of IE62 and IE63 coimmunopre-
cipitated or bound to the gI3.4 promoter in magnetic
bead recruitment assays were analyzed by immunoblots
using chemiluminescent reagents. Quantification was
performed by densitometry using a Bio-Rad (Hercules,
CA) Model GS-700 imaging densitometer. Experimental
signals were normalized to signals obtained from load-
ing controls or immunoblots of serial dilutions of recom-
binant IE62 and IE63/MBP.
Coimmunoprecipitation of IE63 using a monoclonal
IE62 antibody at increasing NaCl concentrations
One hundred microliters protein G–Sepharose (Am-
ersham) was blocked with a 4% milk/phosphate-
buffered saline (PBS) solution for 1 h at 4°C. VZV-
infected MeWo nuclear protein extracts (500 g total
protein) prepared from cells harvested 48 h p.i. as
described by Sommer et al. (2001) were added to the
protein G–Sepharose in combination with the mono-
clonal IE62 antibody H6 (25 l) and 200 l of 100 mM,
150 mM, 200 mM, 300 mM, 500 mM, 750 mM, or 1 M
NaCl in PBS buffer. Incubation and washing of the
protein G-enhanced precipitates were performed as
previously described (Sommer et al., 2001). Bound
proteins were eluted by boiling in SDS–PAGE buffer,
separated by 10% SDS–PAGE, and transferred to nitro-
cellulose membranes. To detect IE62 the polyclonal
IE62 antibody (Spengler et al., 2000) was used as the
primary antibody (1:1000 dilution) and to detect IE63
the polyclonal IE63 antibody (1:2000 dilution) was
used as the primary antibody. Reactive bands were
visualized using goat anti-rabbit immunoglobulin G
(IgG) conjugated with horseradish peroxidase (Chemi-
con, Temecula, CA) in conjunction with Supersignal
West Pico Chemiluminescence substrate (Pierce,
Rockford, IL).
Protein affinity pulldown assays
IE63 and carboxy-terminal deletions of IE63 were ex-
pressed in E. coli as fusion proteins at the carboxy
terminus of the MBP as described by Stevenson et al.
(1996). The recombinant proteins IE63-MBP (MBP63),
MBP63K, MBP63N, and MBP were affinity purified
using amylose resin (New England Biolabs, Beverley,
MA). All steps were performed at 4°C. Bacterial cells
from 500-ml cultures were harvested by low-speed cen-
trifugation and resuspended in 50 ml lysis buffer (10 mM
Na2PO4, 30 mM NaCl, 0.25% Tween 20, 10 mM -mer-
captoethanol, 10 mM EDTA, and 10 mM EGTA). The
suspensions were sonicated and NaCl was added to a
final concentration of 0.5 M. Supernatants were collected
after centrifugation of the lysates at 9,000 g for 30 min.
Approximately 130 l of amylose resin (New England
Biolabs) was washed with 500 l of PBS/1% Triton X-100
(PBST) for 15 min. This was followed by a blocking step
with 5% milk in PBST for 1 h. After blocking, the beads
were washed once with 500 l PBST for 10 min. Next the
amylose resin was incubated with 400 l of the MBP63,
K, or N supernatants. Forty microliters of the MBP
supernatant was used since MBP was expressed at
levels approximately tenfold higher than the IE63-MBP
fusion proteins. These reactions were incubated for 1 h.
The beads were then washed with 500 l of PBST three
times for 10 min each.
The MBP fusion conjugated beads were incubated
with 40 g recombinant IE62 and 200 g BSA, in 300 l
PBST for 3 h. The IE62 was purified from Spodoptera
frugiperda cells infected with recombinant baculovirus
expressing IE62 as previously described (Spengler et al.,
2000). The beads were washed with 500 l PBST three
times for 15 min each. After the last wash, 2 SDS–PAGE
loading buffer was added and the resins were boiled for
10 min. Twenty microliters of each sample was analyzed
on a 10% SDS–PAGE gel and the separated proteins
were transferred to nitrocellulose membranes. To detect
recombinant IE62 the polyclonal IE62 antibody was
used as the primary antibody in the immunoblot proce-
dure.
Analysis of infected cells by laser scanning confocal
microscopy
MeWo cells were seeded onto coverslips in 6-well
dishes, grown in Eagle’s minimal essential medium with
10% fetal bovine serum to confluency, and infected with
VZV-MSP (Santos et al., 1998, 2000). At 15 h p.i. (early) or
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48 h p.i. (late), the infected cells were fixed and perme-
abilized with 2% paraformaldehyde in 0.2 M Na2HPO4
with 0.05% Triton X-100 for 1 h and then washed five
times with PBS (pH 7.4). The samples were blocked with
5% dry milk in PBS (w/v) for 30 min. Primary antibodies
were diluted in PBS containing 1% milk; rabbit polyclonal
IE63 was diluted 1:300 and MAb 5C6, which recognizes
IE62, was diluted 1:1000. After incubation overnight at
4°C and washing with PBS, the samples were incubated
with secondary antibodies and TOTO-3, a DNA marker
(Molecular Probes, Inc.). Secondary antibodies, includ-
ing Texas-red-conjugated goat anti-mouse and Alexa
488-conjugated goat anti-rabbit antibody, were diluted
1:1000 in PBS. Samples were analyzed by laser scanning
confocal microscopy with the accompanying proprietary
software (LSM 510; Zeiss, Germany).
DNA transfections and reporter gene assays
Transfection of A3.01 cells by electroporation with 10
g of CAT reporter plasmids and 0.2 g pCMV62 and/or
1.5 g pCMV63 effector plasmids was performed as
described by Boucaud et al. (1998). Cells were harvested
48 h posttransfection and CAT assays were performed
as previously described (Perera et al., 1992a, 1992b,
1993). The extent of acetylation was quantified by using
a Bio-Rad Phosphoimager and Molecular Imaging Soft-
ware.
Magnetic bead recruitment assays
A 128-bp biotinylated DNA fragment containing the
AUS and TATA elements and 68 bp of downstream se-
quence was generated from the gI3.4CAT reporter plas-
mid using biotinylated primers (IDT, Coralville, IA). Bio-
tinylated gI3.4 DNA (10 pmol) in 100 l of 2 binding and
washing (B&W) buffer [10 mM Tris–HCl (pH 7.5), 1 mM
EDTA, and 2 M NaCl] was added to 50 l of M-280
streptavidin-coated magnetic beads (Dynal, Lake Suc-
cess, NY) which had been prewashed twice with 100 l
of 2 B&W buffer. The mixture was incubated for 15 min
at room temperature. The beads were collected using a
magnetic particle concentrator (Dynal), washed twice
with 200 l of 1 B&W [10 mM Tris–HCl (pH 7.5), 1 mM
EDTA, and 1 M NaCl] buffer, and then washed twice with
200 l of TEN buffer [10 mM Tris–HCl (pH 7.5), 1 mM
EDTA, and 0.1 M NaCl]. Next 500 g, 1 mg, or 2 mg of
VZV-infected MeWo nuclear protein extract alone, or 20
g of recombinant IE62 and/or 20 g IE63/MBP (purified
as described by Spengler et al., 2001) plus 250 g of
uninfected MeWo cell nuclear protein extract, was incu-
bated with the beads for 1 h at 4°C. The reactions were
resuspended three times during the 1-h incubation. Next
the beads were washed three times with 400 l of TEN
buffer. To elute specifically bound proteins the beads
were incubated with 10 l of 2 B&W buffer for 5 min at
room temperature. The eluted fractions were boiled in
2 SDS–PAGE loading buffer for 10 min and analyzed by
10% SDS–PAGE and immunoblotting.
Coimmunoprecipitation of IE63 and RNA polymerase II
Protein G–Sepharose (Amersham) was blocked with a
4% milk/PBS solution for 1 h at 4°C. VZV-infected MeWo
nuclear extract (500 g) was added to the protein
G–Sepharose in combination with a monoclonal RNA
polymerase II antibody (RBP8) or with the polyclonal
IE63 antibody. The reaction was incubated at 4°C for
6 h. Following incubation the reaction mixtures were
centrifuged and washed three times with a PBS/0.1%
Tween 80 solution. The beads were then resuspended in
2 SDS–PAGE loading buffer and boiled for 10 min. The
samples were analyzed on a 10% SDS–PAGE gel and
transferred to nitrocellulose membranes. The polyclonal
IE63 antibody was used as the primary antibody to
detect IE63, and a monoclonal RNAP II antibody (RPB1)
was used as the primary antibody to detect RNAP II in
the Western procedure. Monoclonal antibodies directed
against the RPA70 and RPA32 subunits of RPA, polyclonal
rabbit antibodies directed against RPA32, and monoclo-
nal antibodies directed against mammalian DNA poly-
merase  were used in control experiments for either
immunoprecipitation or immunoblot detection to deter-
mine the specificity of the IE63/RNAP II interaction.
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